Johnson & Johnson (NYSE: JNJ) is one of the top healthcare stocks in the world, with a market cap of around $390 billion. But in recent years, it hasn't exactly been known to be a top growth stock; in five years, the stock has risen by just 18%.

Even if you look at the past decade, it has risen by 76%, which averages out to a compound annual rate of 5.8%, well below the S&P 500's long-run average of 10%.

But Johnson & Johnson spun off its consumer health business last year in order to focus more on growth opportunities. Could the move accelerate its returns and be enough for this stock to reach a $1 trillion valuation by 2030?

Continue reading

Source Fool.com